Richard Stark, a newly reported director at RenovoRx, Inc., filed a Form 3 initial statement of beneficial ownership with the SEC on November 20, 2026, disclosing three fully vested stock options as of the event date of November 18, 2026.

Key Highlights

  • Reporting person: Richard Stark, identified as a Director of RenovoRx, Inc. (NASDAQ:RNXT).
  • No direct stock holdings: Table I of the filing lists no non-derivative securities beneficially owned by Stark.
  • Three stock options disclosed: Options to purchase 46,000, 12,000, and 50,000 shares of Common Stock, with exercise prices of $1.38, $1.02, and $0.98 respectively.
  • Expiration dates: The three options expire on 12/04/2034, 01/05/2036, and 04/02/2036, according to the filing.
  • All options fully vested: The filing states the options "are fully vested and exercisable."
  • Grant basis: According to the filing, the options were granted under RenovoRx's Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services provided to the issuer.

Richard Stark's Initial Beneficial Ownership in RenovoRx Detailed

Richard Stark filed a Form 3 with the SEC on November 20, 2026, with an event date of November 18, 2026, establishing his initial statement of beneficial ownership in RenovoRx, Inc. (NASDAQ:RNXT). The filing identifies Stark solely as a Director of the company and was filed by him as one reporting person.

As disclosed in Table II of the filing, Stark holds three separate stock options, all classified as direct ownership and all described as rights to buy Common Stock. The first option covers 46,000 shares at an exercise price of $1.38, expiring December 4, 2034. The second covers 12,000 shares at $1.02, expiring January 5, 2036. The third covers 50,000 shares at $0.98, expiring April 2, 2036. The filing notes that the date exercisable field is marked with a footnote indicating the options are already fully vested and exercisable.

The filing's explanatory footnote states that all three options "were granted under the Issuer's Amended and Restated 2021 Omnibus Equity Incentive Plan as compensation for consulting services provided to the Issuer and are fully vested and exercisable." No shares of Common Stock or other non-derivative securities are reported as directly or indirectly held by Stark in Table I of the filing.

What Was Disclosed

Richard Stark filed an initial beneficial ownership statement as a Director of RenovoRx, Inc., disclosing three fully vested stock options to purchase a combined 108,000 shares of Common Stock at exercise prices ranging from $0.98 to $1.38, with no direct share holdings reported.